120 results
10-K
2022 FY
OBSVF
ObsEva SA
31 Mar 23
Annual report
4:01pm
”), Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Private Securities Litigation Reform Act of 1995. Written … litigation under federal and state statutes, which can lead to civil and criminal penalties and fines, agreements with governmental authorities that materially
6-K
EX-99.1
OBSVF
ObsEva SA
19 Dec 22
ObsEva Announces Dismissal of Moratorium Proceedings
8:30am
that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act
6-K
EX-99.1
OBSVF
ObsEva SA
14 Dec 22
ObsEva Evidences Compliance with Nasdaq’s Stockholder’s Equity Rule and Announces Moratorium Dismissal Request Filing
7:15am
as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe”, “expect
6-K
EX-99.1
OBSVF
ObsEva SA
9 Dec 22
ObsEva To Increase Issued Share Capital by Creating Additional Treasury Shares
7:09am
not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995
F-3
EX-4.2
OBSVF
ObsEva SA
9 Dec 22
Shelf registration (foreign)
7:06am
BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS INDENTURE.
Section 13.06 Treatment
6-K
pi8qc 3jd2t
1 Dec 22
Index to Unaudited Condensed Consolidated Financial Statements
4:15pm
6-K
EX-99.3
hcv9d5b3ex43a3hbdaws
1 Dec 22
Index to Unaudited Condensed Consolidated Financial Statements
4:15pm
6-K
EX-99.2
rby33l1r0dtkc
22 Nov 22
Consent and Amendment Agreement
7:10am
6-K
zzu8 cda5oo1
22 Nov 22
Consent and Amendment Agreement
7:10am
6-K
EX-99.1
f9los
26 Oct 22
ObsEva Announces Progress on Cost Reduction Initiatives and Stay of
5:11pm
6-K
hjfabu9 ggz
26 Oct 22
ObsEva Announces Progress on Cost Reduction Initiatives and Stay of
5:11pm
6-K
EX-99.1
k81ycv
13 Oct 22
ObsEva Announces IND Approval for Yuyuan Bioscience’s Phase 1 Clinical Trial of Nolasiban in China
7:13am
6-K
EX-99.1
zf3cgqru
13 Sep 22
ObsEva Announces Progress on Restructuring Initiatives
9:13am
6-K
EX-99.1
t88sx9
22 Aug 22
ObsEva Receives Nasdaq Non-Compliance Notice
6:08am
6-K
hb27ksh9
17 Aug 22
Index to Unaudited Condensed Consolidated Financial Statements
4:01pm
6-K
482dskbenihfkmyjv
1 Aug 22
ObsEva Announces $31 million Debt Retirement and $11 million Debt Refinancing
7:21am
6-K
EX-99.1
68mz2bzgs5b5y35ufs9i
1 Aug 22
ObsEva Announces $31 million Debt Retirement and $11 million Debt Refinancing
7:21am
6-K
EX-99.1
s8cgn7s hb
29 Jul 22
ObsEva Announces Management Change
7:06am
6-K
EX-99.2
eyt03e2oo1x ni8ny8c2
27 Jul 22
ObsEva Announces Corporate Updates
7:03am
6-K
EX-99.1
ua5ahc3gu2kspc 8i
27 Jul 22
ObsEva Announces Corporate Updates
7:03am